OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
Ioannis Bellos
Therapeutics and Clinical Risk Management (2021) Vol. Volume 17, pp. 649-656
Open Access | Times Cited: 23
Ioannis Bellos
Therapeutics and Clinical Risk Management (2021) Vol. Volume 17, pp. 649-656
Open Access | Times Cited: 23
Showing 23 citing articles:
KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Olivier Devuyst, Curie Ahn, Thijs R.M. Barten, et al.
Kidney International (2025) Vol. 107, Iss. 2, pp. S1-S239
Open Access | Times Cited: 4
Olivier Devuyst, Curie Ahn, Thijs R.M. Barten, et al.
Kidney International (2025) Vol. 107, Iss. 2, pp. S1-S239
Open Access | Times Cited: 4
Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials
David Alpers, James H. Lewis, Christine M. Hunt, et al.
American Journal of Kidney Diseases (2022) Vol. 81, Iss. 3, pp. 281-293.e1
Open Access | Times Cited: 21
David Alpers, James H. Lewis, Christine M. Hunt, et al.
American Journal of Kidney Diseases (2022) Vol. 81, Iss. 3, pp. 281-293.e1
Open Access | Times Cited: 21
Inhibiting centrosome clustering reduces cystogenesis and improves kidney function in autosomal dominant polycystic kidney disease
Tao Cheng, Aruljothi Mariappan, Ewa Langner, et al.
JCI Insight (2024) Vol. 9, Iss. 4
Open Access | Times Cited: 4
Tao Cheng, Aruljothi Mariappan, Ewa Langner, et al.
JCI Insight (2024) Vol. 9, Iss. 4
Open Access | Times Cited: 4
Electrolyte and metabolite composition of cystic fluid from a rat model of ARPKD
Christine A. Klemens, Mykhailo Fedoriuk, Marharyta Semenikhina, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
Christine A. Klemens, Mykhailo Fedoriuk, Marharyta Semenikhina, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
The Vasopressin Receptor Antagonist Tolvaptan Counteracts Tumor Growth in a Murine Xenograft Model of Small Cell Lung Cancer
Laura Naldi, Benedetta Fibbi, S. Polvani, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8402-8402
Open Access | Times Cited: 3
Laura Naldi, Benedetta Fibbi, S. Polvani, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8402-8402
Open Access | Times Cited: 3
Long-term effectiveness and safety of tolvaptan in autosomal dominant polycystic kidney disease
L Cantarelli, Marta Gutiérrez‐Valencia, Leire Leache, et al.
Medicina Clínica (2024) Vol. 163, Iss. 1, pp. 1-7
Closed Access | Times Cited: 2
L Cantarelli, Marta Gutiérrez‐Valencia, Leire Leache, et al.
Medicina Clínica (2024) Vol. 163, Iss. 1, pp. 1-7
Closed Access | Times Cited: 2
Diet and Polycystic Kidney Disease: Nutrients, Foods, Dietary Patterns, and Implications for Practice
Kelly Lambert, Robert Gardos, Helen Coolican, et al.
Seminars in Nephrology (2023) Vol. 43, Iss. 2, pp. 151405-151405
Closed Access | Times Cited: 4
Kelly Lambert, Robert Gardos, Helen Coolican, et al.
Seminars in Nephrology (2023) Vol. 43, Iss. 2, pp. 151405-151405
Closed Access | Times Cited: 4
Enfermedad renal poliquística autosómica dominante actualización diagnóstico y tratamiento
Diana Nathaly Saez-Paredes, Rosalina de Lourdes Lituma-Jumbo
MQRInvestigar (2024) Vol. 8, Iss. 1, pp. 782-800
Open Access | Times Cited: 1
Diana Nathaly Saez-Paredes, Rosalina de Lourdes Lituma-Jumbo
MQRInvestigar (2024) Vol. 8, Iss. 1, pp. 782-800
Open Access | Times Cited: 1
Novel Potential Therapeutic Targets in Autosomal Dominant Polycystic Kidney Disease from the Perspective of Cell Polarity and Fibrosis
Yejin Ahn, Jong Hoon Park
Biomolecules & Therapeutics (2024) Vol. 32, Iss. 3, pp. 291-300
Open Access | Times Cited: 1
Yejin Ahn, Jong Hoon Park
Biomolecules & Therapeutics (2024) Vol. 32, Iss. 3, pp. 291-300
Open Access | Times Cited: 1
Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion
Elizabeth J. Wilk, Timothy C. Howton, Jennifer L. Fisher, et al.
Molecular Medicine (2023) Vol. 29, Iss. 1
Open Access | Times Cited: 3
Elizabeth J. Wilk, Timothy C. Howton, Jennifer L. Fisher, et al.
Molecular Medicine (2023) Vol. 29, Iss. 1
Open Access | Times Cited: 3
Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment
Pattareeya Yottasan, Tifany Chu, Parth D. Chhetri, et al.
Translational research (2023) Vol. 265, pp. 17-25
Closed Access | Times Cited: 3
Pattareeya Yottasan, Tifany Chu, Parth D. Chhetri, et al.
Translational research (2023) Vol. 265, pp. 17-25
Closed Access | Times Cited: 3
N-(4-acetamidophenyl)-5-acetylfuran-2-carboxamide as a novel orally available diuretic that targets urea transporters with improved PD and PK properties
Shuyuan Wang, Yue Xu, Yan Zhao, et al.
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113859-113859
Closed Access | Times Cited: 7
Shuyuan Wang, Yue Xu, Yan Zhao, et al.
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113859-113859
Closed Access | Times Cited: 7
PKD1 gene mutation and ultrasonographic characterization in cats with renal cysts
Kotchapol Jaturanratsamee, Palin Jiwaganont, Pratch Sukumolanan, et al.
F1000Research (2024) Vol. 12, pp. 760-760
Open Access
Kotchapol Jaturanratsamee, Palin Jiwaganont, Pratch Sukumolanan, et al.
F1000Research (2024) Vol. 12, pp. 760-760
Open Access
Long-term effectiveness and safety of tolvaptan in autosomal dominant polycystic kidney disease
L Cantarelli, M. Valencia, Leire Leache, et al.
Medicina Clínica (English Edition) (2024) Vol. 163, Iss. 1, pp. 1-7
Closed Access
L Cantarelli, M. Valencia, Leire Leache, et al.
Medicina Clínica (English Edition) (2024) Vol. 163, Iss. 1, pp. 1-7
Closed Access
PKD1 gene mutation and ultrasonographic characterization in cats with renal cysts
Kotchapol Jaturanratsamee, Palin Jiwaganont, Pratch Sukumolanan, et al.
F1000Research (2023) Vol. 12, pp. 760-760
Open Access | Times Cited: 1
Kotchapol Jaturanratsamee, Palin Jiwaganont, Pratch Sukumolanan, et al.
F1000Research (2023) Vol. 12, pp. 760-760
Open Access | Times Cited: 1
PKD1 gene mutation and ultrasonographic characterization in cats with renal cysts
Kotchapol Jaturanratsamee, Palin Jiwaganont, Pratch Sukumolanan, et al.
F1000Research (2023) Vol. 12, pp. 760-760
Open Access | Times Cited: 1
Kotchapol Jaturanratsamee, Palin Jiwaganont, Pratch Sukumolanan, et al.
F1000Research (2023) Vol. 12, pp. 760-760
Open Access | Times Cited: 1
The role of tolvaptan in pulmonary hypertension: A retrospective study
Qiaoli Chen, Heng Luo, Yuping Li
Medicine (2022) Vol. 101, Iss. 47, pp. e31587-e31587
Open Access | Times Cited: 2
Qiaoli Chen, Heng Luo, Yuping Li
Medicine (2022) Vol. 101, Iss. 47, pp. e31587-e31587
Open Access | Times Cited: 2
Efficacy of tolvaptan on the short and mid-term prognosis in elderly patients with acute heart failure coexisting with oliguria: A retrospective cohort study
Yang Liu, Yabin Zhang, Hongyu Chen, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 9
Open Access
Yang Liu, Yabin Zhang, Hongyu Chen, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 9
Open Access
Acute nierschade bij patiënten met cirrose: differentiaaldiagnose en praktische aanpak
A.-M. Van der Biest, Jeroen de Filette, E. Hoste, et al.
Tijdschrift voor Geneeskunde (2022)
Closed Access
A.-M. Van der Biest, Jeroen de Filette, E. Hoste, et al.
Tijdschrift voor Geneeskunde (2022)
Closed Access
Can tolvaptan usage cause cytotoxicity? An in vitro study
Beril Erdem Tuncdemir
The European Research Journal (2022) Vol. 9, Iss. 3, pp. 454-460
Open Access
Beril Erdem Tuncdemir
The European Research Journal (2022) Vol. 9, Iss. 3, pp. 454-460
Open Access
Progress in the Diagnosis and Treatment of Traditional Chinese Medicine and Western Medicine for Autosomal Dominant Polycystic Kidney Disease
艾琳 杜
Advances in Clinical Medicine (2022) Vol. 12, Iss. 09, pp. 8487-8492
Closed Access
艾琳 杜
Advances in Clinical Medicine (2022) Vol. 12, Iss. 09, pp. 8487-8492
Closed Access
Inhibition of Centrosome Clustering Reduces Cystogenesis and Improves Kidney Function in Autosomal Dominant Polycystic Kidney Disease
Tao Cheng, Aruljothi Mariappan, Ewa Langner, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Tao Cheng, Aruljothi Mariappan, Ewa Langner, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mousePkd2model gene expression reversion
Elizabeth J. Wilk, Timothy C. Howton, Jennifer L. Fisher, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Closed Access
Elizabeth J. Wilk, Timothy C. Howton, Jennifer L. Fisher, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Closed Access
